GlassScriptPhysician profile
Rafael Begluyan
NPI 1740701572
$7,264.29
in general payments reported to CMS, 2019-2025
25 companies · $535 in 2025
The $535 reported for 2025 was more than what 78% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,888 · 2022: $2,946 · 2023: $1,249 · 2024: $647 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,863.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $1,336.35 | 2021-2025 | |
| Esperion Therapeutics, INC. | $607.81 | 2021-2023 | Nexletol |
| Edwards Lifesciences Corporation | $564.00 | 2024-2025 | Evoque, Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $421.56 | 2021-2023 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.37 | 2021-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $374.78 | 2021-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $196.01 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $193.62 | 2021-2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $186.48 | 2021-2023 | Livalo |
| Amgen INC. | $177.40 | 2021-2025 | Repatha |
| Boston Scientific Corporation | $161.74 | 2024 | Emerge Push |
| United Therapeutics Corporation | $128.06 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $127.35 | 2021-2023 | Amvuttra |
| Novo Nordisk INC | $86.22 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.21 | 2021-2022 | |
| Amarin Pharma, INC. | $72.10 | 2021-2022 | |
| Irhythm Technologies, INC. | $66.91 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Lexicon Pharmaceuticals, INC. | $54.93 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $49.29 | 2022-2023 | Uptravi, Opsumit |
| Astellas Pharma US INC | $45.41 | 2021-2023 | Lexiscan |
| Regeneron Healthcare Solutions, INC. | $34.34 | 2021-2023 | Evkeeza |
| Medicure Pharma INC. | $29.60 | 2021 | |
| Scpharmaceuticals INC. | $17.51 | 2023 | |
| Pfizer INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Begluyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.